Telos Corporation (TLS) Stock Message Board

Play Episode

7min

Proactive - Interviews for investors

Titan Mining reports record 2024 production, expands resources

Titan Mining President Rita Adiani joined Steve Darling from Proactive to discuss the company’s year-end results, highlighting record production and strong financial performance in 2024. The company met the upper end of its production guidance, while costs were 10% lower than the low end of its all-in sustaining cost (AISC) guidance. In Q4 2024, Titan Mining produced 21.7 million pounds of payable zinc, marking a 56% increase compared to Q4 2023. Total full-year 2024 production reached 59.5 million pounds. The company also posted Q4 revenues of $26.3 million, representing a 318% increase from Q3 2024 and a 241% increase from Q4 2023. Adiani also shared updates on the company’s mineral resource expansion, noting that Titan completed an updated mineral resource estimate and extended the mine life for ESM’s zinc operations until 2033. The updated estimate reports a 22% increase in measured and indicated contained zinc pounds compared to the 2020 resource estimate. In addition to its zinc operations, Titan completed a maiden mineral resource estimate for the Kilbourne Graphite Project. The project now holds an open-pit constrained inferred mineral resource of 22 million U.S. short tons, with an average grade of 2.91% (Cg), containing 653,000 tons of graphite at a 1.50% cut-off grade. #proactiveinvestors #titanminingcorporation #tsx #ti #otcqb #timcf #TitanMining #ZincProduction #GraphiteMining #BatteryMetals #CriticalMinerals #MiningStocks #TSX #RitaAdiani #EVMaterials #GraphiteUSA #MiningExpansion #AgustaGroup #ProactiveInvestors

Proactive - Interviews for investors

Lithium ION Energy secures joint venture with SureFQ to advance Urgakh Naran Lithium project

Lithium ION Energy Limited CEO Ali Haji joined Steve Darling from Proactive to announce a binding Joint Venture Agreement with SureFQ for the advancement of the Urgakh Naran lithium project in Mongolia. Under the agreement, ION will retain a 20% free carried interest through to commercial production, ensuring long-term participation in the project's success without additional financial commitments. SureFQ, a firm specializing in sustainable energy solutions and lithium resource development, will leverage its industry expertise and advanced extraction technologies to accelerate the project’s progress. As a strategic investor, SureFQ focuses on developing high-potential assets that support the global energy transition. Haji told Proactive SureFQ will provide $5.5 million in cash considerations to ION over 4.5 years. The company has committed to $8 million in development expenditures for Urgakh Naran over four years. ION Energy will maintain a 2.5% Net Smelter Return (NSR) royalty in perpetuity, ensuring a steady revenue stream from future production. Haji emphasized that ION Energy is a proven Direct Lithium Extraction (DLE) operator, focused on deploying modular extraction capacity to optimize efficiency. This partnership positions Urgakh Naran as a key lithium asset in Mongolia, furthering ION’s role in the global battery metals supply chain. #proactiveinvestors #lithiumionenergylimited #tsxv #ion #urgakhnaran #mongolia #lithium #IonEnergy #AliHaji #UrgakhNaran #SureFQ #MongoliaMining #LithiumExtraction #DLETechnology #BatteryMetals #EVSupplyChain #CriticalMinerals #MiningInvestment #ProactiveInvestors #JuniorMining

Proactive - Interviews for investors

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a clinical trial evaluating the company’s investigational immunotherapy in patients with stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitor (ICI) treatment. The study reported a median overall survival (mOS) of 24.5 months in 46 evaluable patients who received two courses of the investigational therapy. In a subset of patients who had progressive disease at baseline despite ICI treatment, mOS was 21.5 months. Historically, similar patients receiving standard-of-care chemotherapy have had mOS between 9.8 and 11.8 months, with published studies rarely exceeding 12 months. With a median follow-up of 32.4 months, the data demonstrated long-term survival benefits, with 37% of patients who had progressive disease despite ICI therapy still alive two years after treatment. Based on these positive results, Candel Therapeutics will continue advancing the development program, including preparations for a potential registrational trial in patients with non-squamous histology NSCLC. The U.S. Food and Drug Administration (FDA) has previously granted Fast Track Designation for the investigational therapy in combination with an antiviral agent and ICI therapy for patients with stage III/IV NSCLC who are resistant to first-line PD-(L)1 inhibitors and do not have activating molecular driver mutations or have progressed on targeted therapy. These findings support the therapy’s potential as a new treatment option for NSCLC patients with limited alternatives. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

Proactive - Interviews for investors

BioHarvest Sciences reports record-breaking 2024 revenue and expansion milestones

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to discuss the company’s impressive financial and operational performance for the fourth quarter and full year ended December 31, 2024. The company reported a remarkable 62% increase in fourth-quarter revenues, reaching $7.3 million, while full-year revenue surged by 99% year-over-year to $25.2 million, surpassing prior guidance. A key driver of this growth has been the continued expansion of VINIA®, BioHarvest’s flagship product line. As of February 2025, total VINIA® subscribers exceeded 50,000, contributing to a cumulative revenue milestone of $50 million since launch. Building on this momentum, the company successfully introduced its VINIA SuperFood Tea line, leveraging its "VINIA Inside" strategy following the successful launch of VINIA SuperFood Coffee in December 2023. Beyond its financial success, BioHarvest achieved several strategic milestones in 2024. Sobel highlighted a groundbreaking partnership with Tate & Lyle to develop plant-based sweeteners, further validating BioHarvest’s innovative Botanical Synthesis platform. Additionally, the company expanded its VINIA product portfolio and completed a successful uplisting to the Nasdaq Global Market, strengthening its position for accelerated growth and operational efficiency in 2025. With a strong foundation and continued product innovation, BioHarvest Sciences is poised to drive further market expansion and deliver sustained shareholder value in the coming year. #proactivinvestors #nasdaq #bhst #pharma #biotech #hearthealth #fattyliverdisease #BioHarvestSciences, #IlanSobel, #RevenueGrowth, #NasdaqListing, #IlanSobel #VINIA #HealthTech #Biotech LiverHealth #OliveCell #Verbascoside #NonAlcoholicFattyLiver #SupplementScience #HealthInnovation

Followers	0	Posters	1
Posts (Today)	0	Posts (Total)	3
Created	08/14/23	Type	Free
Moderators

Volume:	541,862
Day Range:	2.095 - 2.27
Last Trade Time:	7:35:27 PM EDT

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Telos Corporation (TLS)

TLS Detailed Quote

TLS Latest News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Telos Corporation (TLS)

TLS Latest News

Go Ad-Free